Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab repeated dose-finding study in children and adolescents with polyarticular-course juvenile idiopathic arthritis
2015-003999-79Phase 2
- Sponsor
- Sanofi
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sarilumab in polyarticular juvenile idiopathic arthritis and juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Sanofi. Primary endpoint: Maximum observed serum concentration.
02
Drugs
sarilumab
03
Conditions
polyarticular juvenile idiopathic arthritisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2015-003999-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003999-79.